Pancreatic cancer is a formidable disease, recently rising to the third leading cause of cancer death in the United States. Despite this, the team at Jefferson is bringing hope and healing to patients and families turning to us for expert care with compassion.
Jefferson’s pancreatic cancer program is led by Charles J. Yeo, MD, FACS. Complimenting this clinical care is a robust basic, translational and clinical research program, led by Jonathan R. Brody, PhD and Jordan M. Winter, MD.
The Brody Lab uses and integrates several different models for research investigations, including tissue culture models derived from the patients we treat, commercial cell lines, mouse models with pancreatic cancer, and a clinical database with a complementary biologic tissue repository. With these resources, we are developing innovative strategies to personalize therapy and to better understand how pancreatic cancers develop resistance to standard chemotherapies.
Sky Community Partners is proud and honored to support the innovative work of The Brody Lab.